Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 9/2020

01-09-2020 | Azathioprine | Letter to the Editors

Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy

Authors: Melissa J. Danesh, Patrick M. Mulvaney, Naoka Murakami, Leonardo V. Riella, Ann W. Silk, Glenn J. Hanna, Chrysalyne D. Schmults

Published in: Cancer Immunology, Immunotherapy | Issue 9/2020

Login to get access

Excerpt

To the Editor, …
Literature
1.
Abdel-Wahab N, Safa H, Abudayyeh A et al (2019) Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature. J ImmunoTher Cancer 7(1):106CrossRef
2.
Gupta S, Cortazar FB, Riella LV, Leaf DE (2020) Immune checkpoint inhibitor nephrotoxicity: update 2020. Kidney 1(2):130–140CrossRef
3.
Barnett R, Barta VS, Jhaveri KD (2017) Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab. N Engl J Med 376(2):191–192CrossRef
4.
Tian T, Li X, Zhang J (2019) mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy. Int J Mol Sci 20:3
5.
6.
Dana Farber Cancer Institute (2020) Protocol: 19–817 (IRB pending). A phase I/II study of the safety and efficacy of cemiplimab (PD-1 blockade) in selected organ transplant recipients with advanced cutaneous squamous cell carcinoma (CONTRAC). Principal Investigator: Glenn J. Hanna
7.
Kumar V et al (2020) The safety and efficacy of checkpoint inhibitors in transplant recipients: a case series and systematic review of literature. Oncologist 25(6):505–514 CrossRef
Metadata
Title
Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy
Authors
Melissa J. Danesh
Patrick M. Mulvaney
Naoka Murakami
Leonardo V. Riella
Ann W. Silk
Glenn J. Hanna
Chrysalyne D. Schmults
Publication date
01-09-2020
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 9/2020
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-020-02644-2

Other articles of this Issue 9/2020

Cancer Immunology, Immunotherapy 9/2020 Go to the issue

Original Article

CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer

Original Article

Comparative immunomodulatory properties of mesenchymal stem cells derived from human breast tumor and normal breast adipose tissue

Research Report

Selective targeting of different populations of myeloid-derived suppressor cells by histone deacetylase inhibitors

Original Article

A gene expression-based immune signature for lung adenocarcinoma prognosis

Original Article

Aberrant peripheral blood CD4+ CD25+ FOXP3+ regulatory T cells/T helper-17 number is associated with the outcome of patients with lymphoma

Original Article

Peri-tumor administration of controlled release anti-CTLA-4 synergizes with systemic anti-PD-1 to induce systemic antitumor immunity while sparing autoimmune toxicity
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits